Diseases [C] » Eye Diseases [C11] » Ocular Hypertension » Glaucoma
Description
An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed) MeSH
Hierarchy View
Subtype Terms (4)
Glaucoma, Angle-Closure
15 drugs (12 approved, 3 experimental)
Glaucoma, Neovascular
13 drugs (10 approved, 3 experimental)
Glaucoma, Open-Angle
124 drugs (57 approved, 67 experimental)
Low Tension Glaucoma
10 drugs (7 approved, 3 experimental)
Approved Indicated Drugs (19)
Phase 4 Indicated Drugs (25)
Phase 3 Indicated Drugs (18)
Other Experimental Indicated Drugs (19)
Organization Involved with Phase 4 Indications (113)
Aristotle University of Thessaloniki
Association for Innovation and Biomedical Research on Light and Image (AIBILI)
Beirut Eye Specialist Hospital
Canadian Glaucoma Clinical Research Council
DBYAN Medicine Professional Corporation
European Vision Institute Clinical Research Network
Genovate Biotechnology Co., Ltd.,
Glaucoma Associates of New York
Hospital Carlos G. Durand Buenos Aires
Hospital de Clínicas "Jose de San Martin"
Icahn School of Medicine at Mount Sinai
Innovative Medical Research of South Florida, Inc
I.R.C.C.S. Fondazione Santa Lucia
National University of Singapore
Northwestern Ophthalmic Institute S.C.
Ophthalmic Consultants Centres, Canada
Ophthalmic Consultants of Long Island
Oregon Health and Science University
PRN Pharmacuetical Research Network, LLC
Pro Top & Mediking Company Limited
Robert L. Bacon Medical Foundation
Organization Involved with Phase 3 Indications (51)
Adapt Produtos Oftalmológicos Ltda.
Alfred E. Tiefenbacher (GmbH & Co. KG)
Bagcilar Research and Training Hospital
P. Stradina Clinical University Hospital, Latvia
Shahid Beheshti University of Medical Sciences
Organization Involved with Phase 2 Indications (57)
Alleanza Pharmaceuticals, Inc.
American Society Of Thermalism And Climatology Inc
Asociación para Evitar la Ceguera en México
Clinica Universidad de Navarra
Foundation IRCCS San Matteo Hospital
Industrial Orgánica S.A. de C.V.
National Centre of Ophthalmology named after academician Zarifa Aliyeva
New York Glaucoma Research Institute
Organization Involved with Phase 1 Indications (20)
Organization Involved with Other Experimental Indications (31)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
